文献速递临床试验与 GCP医学人工智能与信息学

使用决策支持对胰岛素治疗患者进行智能糖尿病远程监测(DiaTRUST)试验:随机对照试验研究方案

The intelligent diabetes telemonitoring using decision support to treat patients on insulin therapy (DiaTRUST) trial: study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2024-11-08

DiaTRUST 是一项多中心、3个月、三臂、开放标签随机对照试验,计划纳入51例接受胰岛素治疗的2型糖尿病患者,按3:1:1分为远程监测联合决策支持组、远程监测无决策支持组和常规护理组,使用连接式胰岛素笔、持续葡萄糖监测(CGM)和活动追踪器实施远程监测,评估CGM目标范围内时间、HbA1c、低血糖和高血糖事件、每日胰岛素总剂量、体重、治疗满意度和依从性等结局。

要点

  • 全球成人糖尿病患病率10.5%,2型糖尿病占90-95%。
  • 接受胰岛素治疗的患者中30-50%未达到治疗目标。
  • 试验计划纳入51例接受胰岛素治疗的2型糖尿病患者,按3:1:1随机分组。

核心结论

  • 远程监测联合决策支持有潜力通过提供个体化治疗建议来变革糖尿病管理,从而减轻医疗专业人员负担并改善患者结局。
  • 本研究将为该方法在接受胰岛素治疗的2型糖尿病患者中实现血糖控制的有效性提供有价值的信息。
  • 通过评估临床结局以及患者和医疗专业人员的满意度,本研究旨在为开发高效、可扩展的糖尿病远程医疗解决方案做出贡献。

研究设计与样本

  • 多中心、3个月、三臂、开放标签、随机对照试验。
  • 计划纳入51例接受胰岛素治疗的2型糖尿病患者。
  • 参与者按3:1:1比例分为远程监测联合决策支持组、远程监测无决策支持组和常规护理组。
  • 使用连接式胰岛素笔、持续葡萄糖监测(CGM)和活动追踪器实施远程监测。

主要发现

  • 测量结局包括CGM目标范围内时间、HbA1c、低血糖和高血糖事件、每日胰岛素总剂量、体重、治疗满意度和依从性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Diabetes affects 10.5% of adults globally, with type 2 diabetes accounting for 90-95% of cases. Achieving optimal glycemic control is crucial yet challenging, particularly with insulin therapy, where 30-50% of patients fail to meet treatment targets. Telemedicine can improve diabetes management but generates vast amounts of data, burdening healthcare professionals. Integrating clinical decision support tools into telemonitoring systems may enhance care efficiency and glycemic control. METHODS: The trial is a multicenter 3-month, three-arm, open-label, randomized controlled trial. The trial aims to enroll 51 participants with type 2 diabetes on insulin therapy. Participants will be divided with a 3:1:1 ratio into telemonitoring with decision support, telemonitoring without decision support, and usual care groups. The study employs connected insulin pens, continuous glucose monitors (CGMs), and activity trackers to enable telemonitoring. Outcomes measured include CGM time in range, HbA1c, hypo- and hyperglycemia incidents, total daily insulin dose, body weight, treatment satisfaction, and adherence. DISCUSSION: Telemonitoring with decision support has the potential to revolutionize diabetes management by offering personalized treatment suggestions, thereby reducing the burden on healthcare professionals, and improving patient outcomes. This study will provide valuable insights into the effectiveness of such an approach in achieving glycemic control in people with type 2 diabetes on insulin therapy. By evaluating both clinical outcomes and patient and healthcare professionals' satisfaction, the study aims to contribute to the development of efficient, scalable telehealth solutions for diabetes care. TRIAL REGISTRATION: ClinicalTrials.gov NCT06185296. Registered on December 14, 2023.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Thomsen CHN, Nørlev JTD, Hangaard S, et al. The intelligent diabetes telemonitoring using decision support to treat patients on insulin therapy (DiaTRUST) trial: study protocol for a randomized controlled trial. Trials. 2024. PMID: 39511648. doi:10.1186/s13063-024-08588-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。